What happened with CELZ today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Creative Medical Technology Holdings is developing cell-based treatments, including CELZ-201 CREATE-1 for type 1 diabetes and AlloStemSpine for chronic lower back pain. Both are in clinical trials and require FDA approval before commercialization. The business depends on moving these and other candidates through development into products it can sell itself or through partners.
Its small amount of current product revenue comes from CaverStem kits used in procedures involving a patient’s own cells. Patients pay for these treatments themselves; public and private insurance do not reimburse them. CaverStem is exempt from FDA premarket review and approval, unlike the company’s therapies in clinical trials.
Product revenue does not cover operating costs. The company relies on securities sales to fund development and expects to need additional capital for operations, trials and commercialization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Mesoblast gives Creative Medical investors both a rival and a commercial benchmark for mesenchymal-cell medicines: both develop treatments that include chronic lower-back pain. Watch Mesoblast’s commercial progress for evidence of adoption of this treatment class.
Century Therapeutics competes for the same type 1 diabetes patients Creative Medical aims to treat with cell therapy. Watch its CNTY-813 program, which develops pancreatic beta-islet cells from induced pluripotent stem cells, for progress from this competing approach.
INmune Bio and Creative Medical both need evidence that their cell treatments work, although their lead indications differ. INmune Bio’s CORDStrom mesenchymal stromal-cell program offers a point of comparison for Creative Medical’s regenerative stem-cell treatments, rather than a direct contest for the same patients.
CRISPR Therapeutics pursues the same type 1 diabetes treatment opportunity as Creative Medical, but through a different cellular approach. Its program to replace beta cells is the one to watch alongside Creative Medical’s diabetes cell-therapy development.
Fed Interest Rate Decision
Creative Medical’s Fed-rate decision matters because it can change the interest the company earns on its short-term U.S. Treasury holdings and the cost of future borrowing.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates may increase interest income on Creative Medical’s Treasury holdings, while making any new borrowing more expensive and adding pressure to fund its operations and trials.
If it comes in below expectations
Lower rates may reduce interest income on Creative Medical’s Treasury holdings, but make any new borrowing cheaper, easing that part of the cost of funding its operations and trials.
Creative Medical Technology Holdings, Inc. earningsThis company
Creative Medical’s report will show whether progress in its clinical programs and its minimal CaverStem sales are keeping pace with the cash it uses.
Read operating cash use alongside clinical-program progress and CaverStem sales. Slower cash use, advancing programs and sales that are no longer falling would support the company’s ability to fund development with available cash; faster cash use, stalled programs or further sales declines would make financing or spending cuts more pressing.
CRISPR Therapeutics AG earningsCRSP
CRISPR Therapeutics’ report will show how its beta-cell replacement program is progressing, offering a read on another approach to the type 1 diabetes cell-therapy opportunity Creative Medical is pursuing.
Look for clinical progress in CRISPR Therapeutics’ program and any reported setbacks. Continued progress would show another cell-based approach moving toward the same patient opportunity and could make the competitive field more crowded; a stall or setback would show hurdles for that alternative, not prove Creative Medical’s treatment works.
